Three years ago, I sat across from a founder who was about to make the same mistake I made with we analyzed 10,000 clinical trials: ai predicts drug. I told them the truth.
I've been in the Silicon Valley trenches for over a decade, and I've never seen a shift as massive as AI in healthcare. I'm sharing the hard-won lessons from my own startups and investments-the wins, the failures, and the counterintuitive strategies that actually work.
The Reality Nobody Talks About
Most people approach we analyzed 10,000 clinical trials: ai predicts drug with assumptions that made sense five years ago. The world has moved on. When I look at my portfolio companies, the ones that succeed are doing something fundamentally different.
The first thing to understand is that the data tells a different story than your gut. I've seen this play out across dozens of companies. The pattern is unmistakable.
At RemoteTeam, we learned this the hard way. We spent months going down the wrong path before realizing that the best solutions are often the simplest ones. Once we made the switch, everything changed.
Why Most Approaches Fail
Let me be direct: about 70% of the approaches I see to we analyzed 10,000 clinical trials: ai predicts drug are fundamentally flawed. Not slightly off. Fundamentally flawed.
The root cause is usually one of three things:
- Copying what big companies do without understanding why they do it. What works for Google doesn't work for a 10-person startup.
- Over-engineering the solution when a simple approach would work better. I've seen teams spend six months building something that could have been done in two weeks.
- Ignoring the human element. Technology is the easy part. Getting people to actually use it is where the real challenge lives.
What I've Learned From 107 Companies
After investing in 200+ startups and running two companies to successful exits, I've developed a pretty clear picture of what works with we analyzed 10,000 clinical trials: ai predicts drug.
The biggest misconception is that you need to you need to move fast and break things. That's backwards. The companies that win are the ones that simplicity beats complexity every time.
I remember sitting with the Anthropic team early on and discussing how they thought about we analyzed 10,000 clinical trials: ai predicts drug. Their approach was counterintuitive but brilliant.
The AI Angle
I can't talk about we analyzed 10,000 clinical trials: ai predicts drug in 2026 without mentioning AI. As someone who's invested in Anthropic, OpenAI, Scale AI, and Hugging Face, I have a front-row seat to how AI is transforming this space.
The short version: AI makes good practitioners better and bad practitioners worse. It's an amplifier, not a replacement.
I've seen companies use AI to 10x their we analyzed 10,000 clinical trials: ai predicts drug capabilities. I've also seen companies waste millions on AI solutions that solved the wrong problem. The difference comes down to understanding what you're actually trying to achieve.
This connects to broader themes around clinical AI, healthcare automation, AI mental health, medical AI that I've been thinking about a lot lately.
Final Thoughts
After two exits, 200+ investments, and more mistakes than I can count, here's what I know for sure about we analyzed 10,000 clinical trials: ai predicts drug: there are no shortcuts, but there are smarter paths.
The smartest founders I work with treat we analyzed 10,000 clinical trials: ai predicts drug as a competitive advantage, not a checkbox. They invest in it early, measure it obsessively, and never stop improving.
If you're just getting started with we analyzed 10,000 clinical trials: ai predicts drug, don't be intimidated. Everyone starts somewhere. The key is to start with the right mindset and the right framework, and then execute like your company depends on it. Because it probably does.
Frequently Asked Questions
How can I apply this thinking to my own situation?
Start by identifying the core principle behind the opinion, not the specific example. Then ask yourself: does this principle apply to my context? If yes, test it in a small, low-risk way before going all in.
What's the most common pushback you get on this?
People often push back by citing exceptions or edge cases. And they're usually right that exceptions exist. But building a strategy around exceptions rather than patterns is a losing game for most founders.
What experience informs this perspective?
This perspective comes from over a decade of building companies in Silicon Valley, two successful exits (RemoteTeam to Gusto, MovieLaLa to Gfycat), and investing in 200+ startups including Anthropic, OpenAI, and Scale AI. I write about what I've lived.